Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q2 2025 · 10-Q
Revenue$174.41M$174.41M−4.4% vs Q2 2024 Net Income$31.03M$31.03M−18.2% vs Q2 2024 EPS Diluted$0.64$0.64−12.3% vs Q2 2024 Gross Profit$86,490,000−9.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$35,592,000−48.5% Free Cash Flowderived$25,027,000−60.3% Margins · derivedGross margin49.6%−2.6 pt vs Q2 2024
Operating margin24.2%−6.1 pt vs Q2 2024
Net margin17.8%−3.0 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 7, 2025 · 38 d after period end